6 completed, 4 terminated. 10 Phase 1, 5 Phase 2.
By phase and status
Follow PEGPH20: new trials by email Literature Review of PEGPH20 trials Research Report on PEGPH20
Trials (filtered) newest first · largest first
All 10 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin - Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma Phase 1 / Phase 2 Terminated 219 2017-10-13 2026-08-03 Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic Phase 1 Terminated 85 2017-10-02 2020-02-07 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Nab-Paclitaxel, Gemcitabine, Oxaliplatin - Pancreatic Adenocarcinoma Phase 1 / Phase 2 Completed 341 2017-07-05 2025-11-21 Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase - Metastatic Breast Cancer Phase 1 / Phase 2 Terminated 25 2016-07-13 2020-07-13 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors PEGPH20, Pembrolizumab - NSCLC, Gastric Cancer Phase 1 Completed 56 2015-10-22 2020-02-07 A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC PEGylated recombinant human hyaluronidase PH20, Docetaxel - Non-small Cell Lung Cancer Phase 1 Terminated 16 2015-02-10 2019-02-08 S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer PEGPH20, Oxaliplatin, Leucovorin - Metastatic Pancreatic Adenocarcinoma Phase 1 / Phase 2 Completed 126 2014-01-23 2024-02-09 Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer Gemcitabine, PEGPH20, Placebo - Stage IV Pancreatic Cancer Phase 1 / Phase 2 Completed 28 2011-09-01 2018-11-30 Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors PEGPH20 - Solid Tumor Phase 1 Completed 27 2010-07-01 2014-01-29 Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors PEGPH20 - Solid Tumor Phase 1 Completed 14 2009-02-01 2013-03-26
Conditions studied Neoplasm Metastasis (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Stomach Neoplasms (1)
Sponsors Halozyme Therapeutics (6) · Hoffmann-La Roche (2) · Eisai Inc. (1) · SWOG Cancer Research Network (1)
Countries United States (10) · South Korea (3) · Spain (2) · Australia (1) · Germany (1) · Israel (1) · Japan (1) · Russia (1) · Taiwan (1) · Thailand (1) · United Kingdom (1)
Top investigators Joy Zhu, M.D. (2) · Joy H Zhu, MD, PhD (1) · Ramesh K Ramanathan, M.D. (1)
Results publications PMID 36940261 , PMID 30817250 , PMID 33982408 , PMID 39707623 , PMID 41449151
NIH funding 2016 (2) , 2015 (1) , U10CA180888 (1)